MLTX Stock On Track For Worst Week Since Last Fall As FDA Filing Date For Skin Disease Drug Draws Near
MLTX has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, leaving the stock more than 75% below its 52-week high. MoonLake plans to file with the U.S. Food and Drug Administration (FDA) by the end of September, seeking permission to sell sonelokimab for hidradenitis suppurativa. By late … Read more